Li Xiao Wei
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus (HAI-TL) (NCT06210334) | Li Xiao Wei | 2024-03-01 |
Track Li Xiao Wei automatically
Every clearance here is in the API, with alerts when new ones post.